% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Goldschmidt:153635,
      author       = {H. Goldschmidt and E. K. Mai and J. Dürig and C. Scheid
                      and K. C. Weisel and C. Kunz$^*$ and U. Bertsch and T.
                      Hielscher$^*$ and M. Merz and M. Munder and H.-W. Lindemann
                      and B. Hügle-Dörr and D. Tichy$^*$ and N. Giesen and D.
                      Hose and A. Seckinger and S. Huhn and S. Luntz and A. Jauch
                      and A. Elmaagacli and B. Rabold and S. Fuhrmann and P.
                      Brossart and M. Goerner and H. Bernhard and M. Hoffmann and
                      J. Hillengass and M. S. Raab and I. W. Blau and M. Hänel
                      and H. J. Salwender},
      collaboration = {G. M. M. Group},
      title        = {{R}esponse-adapted lenalidomide maintenance in newly
                      diagnosed myeloma: results from the phase {III} {GMMG}-{MM}5
                      trial.},
      journal      = {Leukemia},
      volume       = {34},
      number       = {7},
      issn         = {1476-5551},
      address      = {London},
      publisher    = {Springer Nature},
      reportid     = {DKFZ-2020-00358},
      pages        = {1853-1865},
      year         = {2020},
      note         = {2020 Jul;34(7):1853-1865},
      abstract     = {The MM5 trial aimed at demonstrating a progression-free
                      survival (PFS) difference in continued vs. response-adapted
                      (in case of complete response, CR) lenalidomide (LEN)
                      maintenance therapy (MT) in newly diagnosed,
                      transplant-eligible multiple myeloma (MM). Patients were
                      equally randomized to receive induction therapy with PAd
                      (bortezomib/doxorubicin/dexamethasone) or VCD
                      (bortezomib/cyclophosphamide/dexamethasone), high-dose
                      melphalan and autologous blood stem cell transplantation,
                      and LEN consolidation, followed by either LEN MT for a fixed
                      duration of 2 years (LEN-2Y) or until achievement of CR
                      (LEN-CR, intention-to-treat population n = 502): arms
                      A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR
                      (n = 126), A2:VCD + LEN-2Y (n = 126),
                      B2:VCD + LEN-CR (n = 125). In the LEN-CR group
                      (B1 + B2), $n = 88/17.5\%$ patients did not start or
                      discontinued LEN MT due to CR. There was no PFS
                      (p = 0.60, primary endpoint) nor overall survival (OS)
                      (p = 0.15) difference between the four study arms. On
                      pooled LEN MT strategies, OS (hazard ratio, hazard ratio
                      [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15,
                      p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y
                      (A1 + A2) groups. PFS was shortened on landmark analyses
                      from the start of LEN MT in patients being in CR in the
                      LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84,
                      p = 0.02). OS from first progression was shortened in
                      the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01).
                      LEN MT should be applied beyond CR for at least 2 years.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32034285},
      doi          = {10.1038/s41375-020-0724-1},
      url          = {https://inrepo02.dkfz.de/record/153635},
}